Faculty

Steven Pergam

Adjunct Professor, Epidemiology
Professor, Medicine - Allergy and Infectious Dis.


Education

MD University of Nebraska, 1998
MPH Epidemiology, University of Washington, 2008

Contact


Fred Hutchinson Cancer Research Center
Box 358080
1100 Fairview Ave. N, E4-100
Seattle, WA 98109
View Website »

Bio

Dr. Pergam is an Infectious Diseases physician and researcher who received his MD from the University of Nebraska School of Medicine, his Infectious Diseases fellowship training at the University of Washington (UW), and his MPH from the UW School of Public Health. Dr. Pergam serves as the Medical Director of Infection Prevention at the Seattle Cancer Care Alliance (SCCA). Dr. Pergam focuses his research on the prevention and treatment of infections among immunocompromised patients, and has expertise in infection prevention and hospital epidemiology among cancer and transplant patients. He serves on numerous national committees, including the CDC’s Advisory Committee on Immunization Practices, and the National Comprehensive Cancer Network Committee on the Prevention and Treatment of Infections in Cancer. He also is an Associate Editor for BMC Infectious Diseases and Current Opinions in Infectious Diseases.

Research Areas

Research Interests

Dr. Pergam’s research interests involve hospital epidemiology, antimicrobial resistance, and infection prevention in immunosuppressed hosts. His research group focuses on infection prevention, resistant pathogens, antimicrobial stewardship, and on the development of novel prevention strategies for community and healthcare-associated infections in cancer and hematopoietic cell transplant patients. He has active research projects that evaluate vaccinations, water-borne pathogens, resistant bacteria, respiratory virus transmission, and fungal infections among immunocompromised hosts. He is interested in the interplay between the immune response, the microbiome, bacterial and viral infections in the respiratory and gastrointestinal systems, and their association with inflammatory complications (e.g. Graft-versus-host disease, mucositis).

Recent Publications (PubMed)

Epidemiology and Outcomes of Recurrent C Difficile Infection Among Hematopoietic Cell Transplant Recipients: A Single-center, Retrospective 10-year Study.
(2024 Oct)
Open Forum Infect Dis 11(10): ofae570
Sanchez E, Krantz EM, Escobar ZK, Tverdek F, Rosen EA, Oshima MU, Carpenter PA, Pergam SA, Liu C
Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients.
(2023 Dec 15)
Clin Infect Dis 77(12): 1723-1732
Thomas LD, Batarseh E, Hamdan L, Haddadin Z, Dulek D, Kalams S, Stewart LS, Stahl AL, Rahman H, Amarin JZ, Hayek H, Ison M, Overton ET, Pergam SA, Spieker AJ, Halasa NB, Adult HCT Flu Study
COVID-19 Outcomes Among Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Recipients in the Era of SARS-CoV-2 Omicron Variants and COVID-19 Therapeutics.
(2024 Nov)
Transplant Cell Ther 30(11): 1108.e1-1108.e11
Rosen EA, Krantz EM, McCulloch DJ, Wilson MH, Tverdek F, Kassamali Escobar Z, Drucker D, Sanchez E, Ueda Oshima M, Mielcarek M, Gauthier J, Pergam SA, Hill JA, Liu C
Ceftriaxone-resistant viridans streptococci bacteraemia among patients treated at a large comprehensive cancer care centre: a retrospective eighteen-year study.
(2024 Aug)
JAC Antimicrob Resist 6(4): dlae126
Marsland P, Jain R, Tverdek F, Hendrie P, Liu C, Pergam SA, Bourassa L
SHEA position statement on pandemic preparedness for policymakers: emerging infectious threats.
(2024 Jul)
Infect Control Hosp Epidemiol 45(7): 818-820
Hsu VP, Pergam SA, Shenoy ES, Banach DB, Jones Batshon L, Branch-Elliman W, Dumyati G, Haessler S, Jump RLP, Malani AN, Mathew TA, Murthy RK, Weber DJ
Show complete publication list